ClinicalTrials.gg
CompletedNCT00159874Updated Feb 1, 2021Results posted

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

A Phase 3 interventional study of Sildenafil citrate and Sildenafil citrate in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 39 sites in 15 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
3rd of 18
234 · median 23
Started
2004
the only one that year
Phase 3
7 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 7 in phase 3, and was the 1st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • children
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must complete the 16 Week double-blind efficacy study A1481131.

Exclusion criteria

Exclusion Criteria:

  • Any patient who did not complete Study A1481131.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Sildenafil high dose

    As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil Low dose

    Drug: Sildenafil citrate

  • Experimental
    Sildenafil medium dose

    As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.

    Drug: Sildenafil citrate

Interventions

  • Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)

  • Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg

  • Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting at Least One Adverse Event

    Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.

    Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)

  2. Number of Participants Reporting Treatment-related Adverse Events

    Safety was measured according to standard adverse event collection as described in the adverse event section of the results.

    Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)

  3. Number of Participants Reporting at Least One Serious Adverse Event

    Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the serious adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.

    Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)

  4. Number of Participants Reporting Treatment-related Serious Adverse Events

    All serious adverse events regardless of treatment group or suspected relationship to study drug were reported. Investigators were to provide independent determination of possible causality of any serious adverse event.

    Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)

  5. Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration

    Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.

    Time frame: Pre-DMC Recommendation dose down titration (04 August 2011)

  6. Number of Deaths Reported During This Study

    Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.

    Time frame: Last follow-up visit or 30 days after the last administration of study drug

  7. Discontinuation Due to Intolerability

    Participant who experienced drug-related intolerance, the participant's dose was reduced by 50%. If, after a dose reduction, the participant continued to appear intolerant, they were discontinued from study treatment.

    Time frame: Throughout the treatment duration (median treatment duration 1689 to 1744 days)

  8. Downtitration in Dose Due to Intolerability.

    Based on review of the survival data, DMC concluded that the high dose of sildenafil was associated with a harmful effect on survival when compared to the low dose. The DMC also expressed concern as to the potential dose-response relationship between increasing dose and mortality. Therefore, on 04 August 2011, the DMC recommended discontinuation of the 40 mg and 80 mg three times a day (TID) doses, as well as the 20 mg TID dose in children with body weight ≤20 kg. The protocol was amended per DMC recommendations.

    Time frame: Pre-DMC recomendation (04 August 2011)

  9. Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests

    Visual Acuity is measured either using the reduced Snellen test or via Teller cards, and was assessed in the left and right eyes separately. There were 9 lines on the reduced Snellen chart which were coded as 6/60, 6/36, 6/24, 6/18, 6/12, 6/9, 6/6, 6/5, 6/4 (where 6/60 was the easiest to read and 6/4 was the most difficult to read). If a participant experienced a visual adverse event the investigator was asked to perform additional ocular assessments either at the visit when the participant reported the visual adverse event or at an unplanned visit.

    Time frame: Week 36

  10. Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests.

    Colour vision was measured where appropriate via the Farnsworth-Munsell D-15 Hue test. This test was performed in both eyes simultaneously or just in a single specific eye. If using a single eye the same eye was used throughout the study. In case of young participants an age-and-ability-appropriate evaluation such as the Ishihara Test for Unlettered Persons were conducted.

    Time frame: Week 36

  11. Pediatric Cognitive Development Status at Week 16.

    Participant's cognitive development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

    Time frame: Week 16

  12. Pediatric Cognitive Development Status at Week 52.

    Participant's cognitive development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

    Time frame: Week 52

  13. Pediatric Motor Development Status at Week 16.

    Participant's motor development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

    Time frame: Week 16

  14. Pediatric Motor Development Status at Week 52

    Participant's motor development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

    Time frame: Week 52

Secondary outcomes

  1. Peak Volume of Oxygen (VO2) Consumed at Year 1 Using a Bicycle Ergometry Cardiopulmonary Exercise Test (CPX)

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the peak volume of VO2 consumed. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant

    Time frame: 1 year

  2. Percentage Change From Baseline in Percent Predicted Peak VO2 at Year 1.

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the percent predicted peak VO2 at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

    Time frame: Baseline, Year 1

  3. Percent Change From Baseline in Time to Maximum VO2 at Year 1

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the time to maximum VO2. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

    Time frame: Baseline, Year 1

  4. Percent Change From Baseline in Respiratory Exchange Ratio at Year 1

    This is the ratio of carbon dioxide (CO2) produced to O2 consumed \[VCO2/VO2\]. Exercise Tolerance Test was performed on developmentally able participants to determine the respiratory exchange ratio on week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913).

    Time frame: Baseline, Year 1

  5. Percent Change From Start of Sildenafil in Total Ventilation (VE) to Year 1

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the total ventilation. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

    Time frame: Year 1

  6. Percentage Change From Baseline in End Tidal Oxygen (O2) at Year 1.

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal O2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

    Time frame: Baseline, Year 1

  7. Percentage Change From Baseline in End Tidal Carbon Dioxide (CO2) at Year 1.

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal CO2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

    Time frame: Baseline, Year 1

  8. Percentage Change From Baseline in Anaerobic Threshold at Year 1.

    Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the anaerobic threshold at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

    Time frame: Baseline, Year 1

  9. Summary of Shift in Changes From Start of Sildenafil in World Health Organization Pulmonary Hypertension (WHO PH) Functional Class by A1481156 Treatment Group at Year 1.

    The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarized at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.

    Time frame: Baseline, Year 1

  10. Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 2.

    The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.

    Time frame: Baseline, Year 2

  11. Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 3.

    The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 (NCT00159913) baseline at Years 1, 2, 3 and 4 were evaluated.

    Time frame: Baseline, Year 3

  12. Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 4.

    The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.

    Time frame: Baseline, Year 4

  13. Additions From Baseline in Background Therapy up to the End of Study

    This was defined as an addition or discontinuation in the class(es) of drugs used as background medication (e.g., anticoagulants, oxygen, diuretics, calcium channel blockers, and digoxin) compared to baseline of Study A1481131 (NCT00159913).

    Time frame: Up to the end of study

  14. Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Psychosocial Scale at Year 1.

    CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

    Time frame: Baseline, Year 1

  15. Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Physical Scale at Year 1.

    CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

    Time frame: Baseline, Year 1

  16. Participant (Parent) Global Assessment at Year 1

    The participant (parent) global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.

    Time frame: Year 1

  17. Physician Global Assessment at Year 1

    The physician global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants with markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.

    Time frame: Year 1

07

Results

Posted Aug 11, 2014

Participant flow

This extension study included 220 participants at 31 sites. 14 participants did not go from A1481131 (NCT00159913) to A1481156. Participants from one center in Canada participated in base study A1481131 (NCT00159913) but not in this extension study.

Participant flow — Overall Study
MilestoneSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Started4255771319235
Treated4255771319235
Completed222534711110
Not completed20304368125
Withdrew: Adverse event2251120
Withdrew: Does not meet entrance criteria1010000
Withdrew: Lack of efficacy2011030
Withdrew: Lost to follow-up1030121
Withdrew: Other8880213
Withdrew: Protocol violation0520000
Withdrew: Death38150120
Withdrew: Withdrawal by subject2684321
Withdrew: Pregnancy1100000

Outcome measures

PrimaryNumber of Participants Reporting at Least One Adverse Event

Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.

Time frame:
Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Reported as:
Number · Participants
Number of Participants Reporting at Least One Adverse Event
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Number of Participants Reporting at Least One Adverse Event4155731319223
PrimaryNumber of Participants Reporting Treatment-related Adverse Events

Safety was measured according to standard adverse event collection as described in the adverse event section of the results.

Time frame:
Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Reported as:
Number · Participants
Number of Participants Reporting Treatment-related Adverse Events
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Number of Participants Reporting Treatment-related Adverse Events20244199113
PrimaryNumber of Participants Reporting at Least One Serious Adverse Event

Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the serious adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.

Time frame:
Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Reported as:
Number · Participants
Number of Participants Reporting at Least One Serious Adverse Event
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Number of Participants Reporting at Least One Serious Adverse Event13333814100
PrimaryNumber of Participants Reporting Treatment-related Serious Adverse Events

All serious adverse events regardless of treatment group or suspected relationship to study drug were reported. Investigators were to provide independent determination of possible causality of any serious adverse event.

Time frame:
Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Reported as:
Number · Participants
Number of Participants Reporting Treatment-related Serious Adverse Events
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Number of Participants Reporting Treatment-related Serious Adverse Events1140000
PrimaryNumber of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration

Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.

Time frame:
Pre-DMC Recommendation dose down titration (04 August 2011)
Reported as:
Number · Participants
Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration51022
PrimaryNumber of Deaths Reported During This Study

Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.

Time frame:
Last follow-up visit or 30 days after the last administration of study drug
Reported as:
Number · Participants
Number of Deaths Reported During This Study
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Number of Deaths Reported During This Study51324
PrimaryDiscontinuation Due to Intolerability

Participant who experienced drug-related intolerance, the participant's dose was reduced by 50%. If, after a dose reduction, the participant continued to appear intolerant, they were discontinued from study treatment.

Time frame:
Throughout the treatment duration (median treatment duration 1689 to 1744 days)
Reported as:
Number · Participants
Discontinuation Due to Intolerability
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Discontinuation Due to Intolerability213
PrimaryDowntitration in Dose Due to Intolerability.

Based on review of the survival data, DMC concluded that the high dose of sildenafil was associated with a harmful effect on survival when compared to the low dose. The DMC also expressed concern as to the potential dose-response relationship between increasing dose and mortality. Therefore, on 04 August 2011, the DMC recommended discontinuation of the 40 mg and 80 mg three times a day (TID) doses, as well as the 20 mg TID dose in children with body weight ≤20 kg. The protocol was amended per DMC recommendations.

Time frame:
Pre-DMC recomendation (04 August 2011)
Reported as:
Number · Participants
Downtitration in Dose Due to Intolerability.
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Downtitration in Dose Due to Intolerability.0030210
PrimaryNumber of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests

Visual Acuity is measured either using the reduced Snellen test or via Teller cards, and was assessed in the left and right eyes separately. There were 9 lines on the reduced Snellen chart which were coded as 6/60, 6/36, 6/24, 6/18, 6/12, 6/9, 6/6, 6/5, 6/4 (where 6/60 was the easiest to read and 6/4 was the most difficult to read). If a participant experienced a visual adverse event the investigator was asked to perform additional ocular assessments either at the visit when the participant reported the visual adverse event or at an unplanned visit.

Time frame:
Week 36
Reported as:
Number · Participants
Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests1011170440
PrimaryNumber of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests.

Colour vision was measured where appropriate via the Farnsworth-Munsell D-15 Hue test. This test was performed in both eyes simultaneously or just in a single specific eye. If using a single eye the same eye was used throughout the study. In case of young participants an age-and-ability-appropriate evaluation such as the Ishihara Test for Unlettered Persons were conducted.

Time frame:
Week 36
Reported as:
Number · Participants
Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests.
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests.2210011
PrimaryPediatric Cognitive Development Status at Week 16.

Participant's cognitive development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

Time frame:
Week 16
Reported as:
Number · Participants
Pediatric Cognitive Development Status at Week 16.
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Severely Limited2420110
Moderately Limited5681521
Mildly Limited67121110
Not Limited2638541112191
PrimaryPediatric Cognitive Development Status at Week 52.

Participant's cognitive development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

Time frame:
Week 52
Reported as:
Number · Participants
Pediatric Cognitive Development Status at Week 52.
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High Dose
Severely Limited112000
Moderately Limited5106152
Mildly Limited358033
Not Limited273650111015
PrimaryPediatric Motor Development Status at Week 16.

Participant's motor development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

Time frame:
Week 16
Reported as:
Number · Participants
Pediatric Motor Development Status at Week 16.
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Severely Limited0000100
Moderately Limited5570411
Mildly Limited1011201520
Not Limited243949129201
PrimaryPediatric Motor Development Status at Week 52

Participant's motor development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.

Time frame:
Week 52
Reported as:
Number · Participants
Pediatric Motor Development Status at Week 52
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High Dose
Severely Limited000000
Moderately Limited495020
Mildly Limited8815363
Not Limited24354691017
SecondaryPeak Volume of Oxygen (VO2) Consumed at Year 1 Using a Bicycle Ergometry Cardiopulmonary Exercise Test (CPX)

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the peak volume of VO2 consumed. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant

Time frame:
1 year
Reported as:
Mean · mL/kg/min
Peak Volume of Oxygen (VO2) Consumed at Year 1 Using a Bicycle Ergometry Cardiopulmonary Exercise Test (CPX)
mL/kg/minSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Peak Volume of Oxygen (VO2) Consumed at Year 1 Using a Bicycle Ergometry Cardiopulmonary Exercise Test (CPX)19.97 ± 5.1718.69 ± 5.9217.93 ± 4.02
Statistical analysis
  • Sildenafil Low Dose vs Sildenafil Medium Dose · ANCOVA · p = 0.253 · Least square mean difference: -7.02 · 95% CI -19.13 to 5.09Least square mean difference of -7.02 was calculated as ' Sildenafil Medium Dose - Low Dose'
  • Sildenafil Low Dose vs Sildenafil High Dose · ANCOVA · p = 0.100 · Least square mean difference: -9.84 · 95% CI -21.60 to 1.93Least square mean difference of -9.84 was calculated as ' Sildenafil High Dose - Low Dose'
  • Sildenafil Medium Dose vs Sildenafil High Dose · ANCOVA · p = 0.640 · Least square mean difference: -2.82 · 95% CI -14.75 to 9.11Least square mean difference of -2.82 was calculated as ' Sildenafil High Dose - Medium Dose'
SecondaryPercentage Change From Baseline in Percent Predicted Peak VO2 at Year 1.

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the percent predicted peak VO2 at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

Time frame:
Baseline, Year 1
Reported as:
Mean · Percent
Percentage Change From Baseline in Percent Predicted Peak VO2 at Year 1.
PercentSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Percentage Change From Baseline in Percent Predicted Peak VO2 at Year 1.12.79 ± 22.717.65 ± 34.575.83 ± 23.548.70 ± 25.990.20 ± 22.32-6.13 ± 7.46NA ± NA
SecondaryPercent Change From Baseline in Time to Maximum VO2 at Year 1

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the time to maximum VO2. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

Time frame:
Baseline, Year 1
Reported as:
Mean · Percent
Percent Change From Baseline in Time to Maximum VO2 at Year 1
PercentSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Percent Change From Baseline in Time to Maximum VO2 at Year 125.47 ± 35.6713.08 ± 33.427.70 ± 33.0121.17 ± 57.2536.68 ± 101.65-9.64 ± 15.21NA ± NA
SecondaryPercent Change From Baseline in Respiratory Exchange Ratio at Year 1

This is the ratio of carbon dioxide (CO2) produced to O2 consumed \[VCO2/VO2\]. Exercise Tolerance Test was performed on developmentally able participants to determine the respiratory exchange ratio on week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913).

Time frame:
Baseline, Year 1
Reported as:
Mean · Percent
Percent Change From Baseline in Respiratory Exchange Ratio at Year 1
PercentSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Percent Change From Baseline in Respiratory Exchange Ratio at Year 12.15 ± 8.735.63 ± 13.370.68 ± 11.50-3.69 ± 7.240.27 ± 11.0410.75 ± 17.76NA ± NA
SecondaryPercent Change From Start of Sildenafil in Total Ventilation (VE) to Year 1

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the total ventilation. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

Time frame:
Year 1
Reported as:
Mean · Percent
Percent Change From Start of Sildenafil in Total Ventilation (VE) to Year 1
PercentSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Percent Change From Start of Sildenafil in Total Ventilation (VE) to Year 114.29 ± 21.3812.38 ± 32.6411.80 ± 19.79
SecondaryPercentage Change From Baseline in End Tidal Oxygen (O2) at Year 1.

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal O2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

Time frame:
Baseline, Year 1
Reported as:
Mean · Percent
Percentage Change From Baseline in End Tidal Oxygen (O2) at Year 1.
PercentSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Percentage Change From Baseline in End Tidal Oxygen (O2) at Year 1.0.59 ± 3.79-0.52 ± 3.550.08 ± 3.68
SecondaryPercentage Change From Baseline in End Tidal Carbon Dioxide (CO2) at Year 1.

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal CO2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

Time frame:
Baseline, Year 1
Reported as:
Mean · Percent
Percentage Change From Baseline in End Tidal Carbon Dioxide (CO2) at Year 1.
PercentSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Percentage Change From Baseline in End Tidal Carbon Dioxide (CO2) at Year 1.7.83 ± 16.357.68 ± 18.7413.16 ± 31.38
SecondaryPercentage Change From Baseline in Anaerobic Threshold at Year 1.

Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the anaerobic threshold at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.

Time frame:
Baseline, Year 1
Reported as:
Mean · Percent
Percentage Change From Baseline in Anaerobic Threshold at Year 1.
PercentSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Percentage Change From Baseline in Anaerobic Threshold at Year 1.-1.22 ± 23.061.99 ± 29.543.28 ± 29.367.23 ± 12.31-3.59 ± 28.298.96 ± 32.55NA ± NA
SecondarySummary of Shift in Changes From Start of Sildenafil in World Health Organization Pulmonary Hypertension (WHO PH) Functional Class by A1481156 Treatment Group at Year 1.

The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarized at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.

Time frame:
Baseline, Year 1
Reported as:
Number · Participants
Summary of Shift in Changes From Start of Sildenafil in World Health Organization Pulmonary Hypertension (WHO PH) Functional Class by A1481156 Treatment Group at Year 1.
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Improved by 3 Classes000
Improved by 2 Classes101
Improved by 1 Class131519
No change304864
Worsened by 1 Class463
Worsened by 2 Classes100
Worsened by 3 Classes000
Discontinued5410
Died001
Missing112
SecondarySummary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 2.

The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.

Time frame:
Baseline, Year 2
Reported as:
Number · Participants
Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 2.
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Improved by 3 Classes000
Improved by 2 Classes011
Improved by 1 Class111116
No change284755
Worsened by 1 Class325
Worsened by 2 Classes000
Worsened by 3 Classes000
Discontinued9916
Died125
Missing322
SecondarySummary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 3.

The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 (NCT00159913) baseline at Years 1, 2, 3 and 4 were evaluated.

Time frame:
Baseline, Year 3
Reported as:
Number · Participants
Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 3.
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Improved by 3 Classes000
Improved by 2 Classes101
Improved by 1 Class111617
No change213644
Worsened by 1 Class335
Worsened by 2 Classes101
Worsened by 3 Classes000
Discontinued141319
Died239
Missing234
SecondarySummary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 4.

The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.

Time frame:
Baseline, Year 4
Reported as:
Number · Participants
Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 4.
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Improved by 3 Classes000
Improved by 2 Classes002
Improved by 1 Class131416
No change152941
Worsened by 1 Class645
Worsened by 2 Classes121
Worsened by 3 Classes000
Discontinued151820
Died2513
Missing322
SecondaryAdditions From Baseline in Background Therapy up to the End of Study

This was defined as an addition or discontinuation in the class(es) of drugs used as background medication (e.g., anticoagulants, oxygen, diuretics, calcium channel blockers, and digoxin) compared to baseline of Study A1481131 (NCT00159913).

Time frame:
Up to the end of study
Reported as:
Number · Participants
Additions From Baseline in Background Therapy up to the End of Study
ParticipantsSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
All Classes (N = 18, 26, 43, 7, 8, 14, 4)65112121
At least one class (N = 42, 55, 77, 13, 19, 23, 5)1313233521
SecondaryChange From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Psychosocial Scale at Year 1.

CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

Time frame:
Baseline, Year 1
Reported as:
Mean · Units on a scale
Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Psychosocial Scale at Year 1.
Units on a scaleSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Psychosocial Scale at Year 1.5.63 ± 7.703.92 ± 10.253.48 ± 12.5513.74 ± 12.425.30 ± 9.304.27 ± 12.19NA ± NA
SecondaryChange From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Physical Scale at Year 1.

CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

Time frame:
Baseline, Year 1
Reported as:
Mean · Units on a scale
Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Physical Scale at Year 1.
Units on a scaleSildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomized
Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Physical Scale at Year 1.14.29 ± 11.069.34 ± 13.455.91 ± 10.178.51 ± 13.279.86 ± 17.934.64 ± 12.03NA ± NA
SecondaryParticipant (Parent) Global Assessment at Year 1

The participant (parent) global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.

Time frame:
Year 1
Reported as:
Number · Participants
Participant (Parent) Global Assessment at Year 1
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Markedly Improved91421
Moderately Improved132726
Mild Improvement121515
No Change13621
Slightly Worse120
Moderately Worse010
Markedly Worse000
Discontinued5410
Died001
Missing256
SecondaryPhysician Global Assessment at Year 1

The physician global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants with markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.

Time frame:
Year 1
Reported as:
Number · Participants
Physician Global Assessment at Year 1
ParticipantsSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Markedly Improved666
Moderately Improved81827
Mild Improvement192637
No Change151617
Slightly Worse110
Moderately Worse010
Markedly Worse000
Discontinued5410
Died001
Missing122

Adverse events

Collected over Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil Low Dose—14/55 (25.5%)51/55 (92.7%)
Sildenafil Medium Dose—37/74 (50%)70/74 (94.6%)
Sildenafil High Dose—48/100 (48%)87/100 (87%)
Most frequent serious events
Showing 10 of 111
Most frequent serious events
EventSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
PneumoniaInfections and infestations1/557/7410/100
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders0/552/747/100
Cardiac failureCardiac disorders2/552/746/100
Upper respiratory tract infectionInfections and infestations0/551/746/100
Chest painGeneral disorders3/550/742/100
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders2/554/745/100
Right ventricular failureCardiac disorders2/553/743/100
GastroenteritisInfections and infestations0/553/743/100
SyncopeNervous system disorders2/552/741/100
Dental cariesGastrointestinal disorders0/551/743/100
Most frequent other events
Showing 10 of 55
Most frequent other events
EventSildenafil Low DoseSildenafil Medium DoseSildenafil High Dose
Upper respiratory tract infectionInfections and infestations9/5522/7437/100
HeadacheNervous system disorders18/5518/7426/100
PharyngitisInfections and infestations16/5513/7413/100
NasopharyngitisInfections and infestations15/5511/7417/100
VomitingGastrointestinal disorders14/5513/7424/100
PyrexiaGeneral disorders7/5516/7416/100
BronchitisInfections and infestations10/5516/7416/100
CoughRespiratory, thoracic and mediastinal disorders11/5514/7417/100
DiarrhoeaGastrointestinal disorders10/5511/7416/100
InfluenzaInfections and infestations10/556/7412/100

Baseline characteristics

Age, Customized
Age, Customized(Participants)Sildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomizedTotal
1-40919132135
5-122528361110142126
13-17171822167273
>=1800000000
Sex: Female, Male
Sex: Female, Male(Participants)Sildenafil Low/Low DoseSildenafil Medium/ Medium DoseSildenafil High/ High DosePlacebo/ Low DosePlacebo/ Medium DosePlacebo/ High DosePlacebo Non-randomizedTotal
Female253151911153145
Male172426488289
08

Study locations

39 sites
  • Pfizer Investigational Site
    Palo Alto, California 34304, United States
  • Pfizer Investigational Site
    Palo Alto, California 94305, United States
  • Pfizer Investigational Site
    Stanford, California 94305, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80045, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02115, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43205, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Seattle, Washington 98105, United States
  • Pfizer Investigational Site
    Sao Paulo, SP 04012-909, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04023-062, Brazil
  • Pfizer Investigational Site
    Puente Alto, Santiago, Chile
  • Pfizer Investigational Site
    Medellin, Antioquia, Colombia
  • Pfizer Investigational Site
    Bogota, Cundinamarca, Colombia
  • Pfizer Investigational Site
    Guatemala, Guatemala
  • Pfizer Investigational Site
    Budapest, 1083, Hungary
  • Pfizer Investigational Site
    Budapest, 1096, Hungary
  • Pfizer Investigational Site
    Szeged, 6720, Hungary
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 001, India
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 073, India
  • Pfizer Investigational Site
    Kochi, Kerala 682 041, India
  • Pfizer Investigational Site
    Bologna, 40138, Italy
  • Pfizer Investigational Site
    Tokyo, Japan
  • Pfizer Investigational Site
    Penang, 10050, Malaysia
  • Pfizer Investigational Site
    Penang, 10900, Malaysia
  • Pfizer Investigational Site
    Penang, 11600, Malaysia
  • Pfizer Investigational Site
    Mexico, DF 14080, Mexico
  • Pfizer Investigational Site
    Krakow, 30-663, Poland
  • Pfizer Investigational Site
    Ruda Slaska, 41-703, Poland
  • Pfizer Investigational Site
    Warszawa, 04-730, Poland
  • Pfizer Investigational Site
    Zabrze, 41-800, Poland
  • Pfizer Investigational Site
    Moscow, 115478, Russian Federation
  • Pfizer Investigational Site
    Moscow, 125412, Russian Federation
  • Pfizer Investigational Site
    Lund, 221 85, Sweden
  • Pfizer Investigational Site
    Kaohsiung, 81346, Taiwan
  • Pfizer Investigational Site
    Taipei, 100, Taiwan
  • Pfizer Investigational Site
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Russell S, Beghetti M, Oudiz R, Balagtas C, Zhang M, Ivy D. Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial. Open Heart. 2019 Dec 3;6(2):e001149. doi: 10.1136/openhrt-2019-001149. eCollection 2019. PubMed 31908813 ↗
  • Chanu P, Gao X, Bruno R, Claret L, Harnisch L. A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):499-509. doi: 10.1007/s10928-019-09654-3. Epub 2019 Sep 20. PubMed 31538282 ↗
  • Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD; STARTS-2 Investigators. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014 May 13;129(19):1914-23. doi: 10.1161/CIRCULATIONAHA.113.005698. Epub 2014 Mar 17. PubMed 24637559 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jan 2004
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Aug 11, 2014
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00159874
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jan 2004
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Aug 11, 2014
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion